Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Section Navigation
			
			CDC Home








Health Effects of Occupational Exposure to Silver Nanomaterials										Related Pages
					May 2021
DHHS (NIOSH) Publication Number 2021-112
PDF Cover image thumbnail
Nanoscale silver particles are some of the most widely used nanomaterials in commerce, with numerous uses in consumer and medical products. Workers who produce or use silver nanomaterials are potentially exposed to those materials in the workplace. Previous authoritative assessments of occupational exposure to silver did not account for particle size. The National Institute for Occupational Safety and Health (NIOSH) assessed potential health risk from occupational exposure to silver nanomaterials by evaluating more than 100 studies of silver nanomaterials in animals or cells. In studies that involved human cells, silver nanomaterials were associated with toxicity (cell death and DNA damage) that varied according to the size of the particles. In animals exposed to silver nanomaterials by inhalation or other routes of exposure, silver tissue concentrations were elevated in all organs tested. Exposure to silver nanomaterials in animals was associated with decreased lung function, inflamed lung tissue, and histopathological (microscopic tissue) changes in the liver and kidney. In the relatively few studies that compared the effects of exposure to nanoscale or microscale silver, nanoscale particles had greater uptake and toxicity than did microscale particles. To date, researchers have not reported health effects in workers exposed to silver nanomaterials.
To assess the risk of adverse health effects from occupational exposure, NIOSH evaluated the data from two published subchronic (intermediate duration) inhalation studies in rats. These studies revealed lung and liver effects that included early-stage lung inflammation and liver bile duct hyperplasia. NIOSH researchers used the data from these studies to estimate the dose of silver nanoparticles that caused these effects in rats. They then calculated the corresponding dose that would be expected to cause a similar response in humans, accounting for uncertainties in those estimates. From this evaluation, NIOSH derived a recommended exposure limit (REL) for silver nanomaterials (<100 nm primary particle size) of 0.9 micrograms per cubic meter (μg/m3) as an airborne respirable 8-hour time-weighted average (TWA) concentration. In addition, NIOSH continues to recommend a REL of 10 μg/m3 as an 8-hour TWA for total silver (metal dust, fume, and soluble compounds, as Ag). NIOSH further recommends the use of workplace exposure assessments, engineering controls, safe work procedures, training and education, and established medical surveillance approaches to protect workers.
**CURRENT INTELLIGENCE BULLETIN 70 Health Effects of Occupational Exposure to Silver Nanomaterials [PDF – 12 MB]**
Suggested Citation
NIOSH [2021]. Current Intelligence Bulletin 70: health effects of occupational exposure to silver nanomaterials. By Kuempel E, Roberts JR, Roth G, Dunn KL, Zumwalde R, Drew N, Hubbs A, Trout D, and Holdsworth G. Cincinnati, OH: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2021-112, https://doi.org/10.26616/NIOSHPUB2021112.Document Development History
CDC – NIOSH Peer Review – Silver Nanomaterials
CDC – NIOSH Docket: Health Effects of Occupational Exposure to Silver Nanomaterials
							
					
							Last Reviewed:  May 18, 2021						Source: 	National Institute for Occupational Safety and Health
					Facebook
        Twitter
        LinkedIn
        Syndicate homeNIOSH Publications & Products
NIOSH-Issued Publications
Search NIOSHTIC-2 Research Database
Docket
Documents for Public Review
Peer Review Agenda
Databases
eNews
Federal Register Noticesplus icon
FRN Archive 2007-2010
FRN Archive 2005-2006
FRN Archive 2001-2004
FRN Archive 1996-2000
Press Releases and Updatesplus icon
Press Release Archives 2010-2013
Press Release Archives 2006-2009
Press Release Archives 2001-2005
Press Release Archives 1998-2000
Press Release Archives 1992-1997
Regulations
Regulatory Agenda
Science Blog
Software
Video Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue